In the company’s news yesterday,
QuantRx Biomedical Corp. announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent extending its lateral flow testing intellectual property suite. This new patent will add significant protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Together with the patented Q-reader technology, QuantRx is able to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer.
“This milestone event for QuantRx marks the culmination of over a decade of research by our exceptional R&D team,” stated Dr. William Fleming, President of Diagnostics at QuantRx. “RapidSense® with its exceptional low level sensitivity, coupled with our unique device technology, allows QuantRx to capitalize on its knowledge base to create tests that, until now, have been limited to laboratory or simple qualitative testing. QuantRx believes that it will offer products that uniquely meet the healthcare needs described by the new U.S. Administration.”
“Our continually expanding intellectual property suite allows QuantRx to enter untouched markets,” added Mr. Walter Witoshkin, QuantRx’ Chairman and CEO. “We are excited by these recent developments which provide a clear path to bring real innovation to the broad U.S. POC marketplace.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
